Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Extra funding for Canadian cervical cancer network:

This article was originally published in Clinica

Executive Summary

The Canadian government is to give Can$670,000 ($482,000) over three years to support the country's cervical cancer network. The funds will be given to the Cervical Cancer Prevention Network and the Nova Scotia Gynaecological Cancer Screening Programme, which will divide the money between a collaborative project and a pilot study. Some 35% of Canadian women aged 18-24 and almost 30% of women over 65 have never been screened for cervical cancer. Each year, over 200,000 pre-cancerous cervical abnormalities are reported in Canada.

You may also be interested in...



Sanofi CEO Hudson Delivers An Ambitious Turnaround Agenda

CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model. 

Sanofi Has The Fire Power For Deals, CEO Hudson Says

The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.

Corindus Envisions Network Of CorPath Robots For Remote Neurovascular And Coronary Interventions

The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.

Topics

UsernamePublicRestriction

Register

MT084307

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel